NuProbe published research on DNA microsatellites in Nucleic Acids Research and released VarTrace® MSI qPCR research use only assay.
Read More
Research published in Nature Biomedical Engineering demonstrates NuProbe’s technology can enable detecting SNVs in DNA with a VAF of ≤0.02% using a sequencing depth of only 250x.
The VarMap Pan-Cancer NGS Panel uses the quantitative blocker displacement amplification technology to enrich, detect, and quantitate over 6500 mutations and indels in 61 clinically relevant genes. The panel can be used on cfDNA samples to detect mutations down to 0.1% variant allele frequency (VAF) using only 1 million NGS reads. The panel can also be applied to FFPE tumor samples or other cellular samples for minimum residual disease (MRD) detection, detecting mutations down to 0.01% VAF.
NuProbe launches the Augury™ platform for automated design of customized liquid biopsy NGS panels. Based on proprietary sequence-design algorithms, Augury™ will procedurally generate NGS panels for cell-free DNA (cfDNA) analysis, covering the entire coding regions of between 1 and 30 genes of interest.
The first, Non-Extensible Oligonucleotides (NEO), will allow NuProbe to provide much more rapid development of customized NGS panels, with turnaround time of less than 4 weeks. The second, Linear DNA Assembly (LDA) technology, improves the effective throughput of nanopore sequencing by up to 10-fold for short DNA, such as DNA extracted from FFPE tumor tissues and cell-free DNA from peripheral blood. Concurrently, NuProbe announces the launch of its new VarMap™ Nanopore product line.
NuProbe Global launches VarTrace™ product line of Sanger assays for ultrasensitive detection and quantification of cancer mutations with variant allele frequencies (VAF) down to 0.1%.
